PASG
Passage Bio, Inc.
Price Chart
Latest Quote
$5.72
+0.13 (+2.33%)
Current Price
| Previous Close | $5.59 |
| Open | $5.60 |
| Day High | $5.85 |
| Day Low | $5.60 |
| Volume | 37,783 |
Stock Information
| Shares Outstanding | 3.21M |
| Total Debt | $5.75M |
| Cash Equivalents | $33.34M |
| Net Income | $-37.68M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $18.35M |
| EPS (TTM) | $-11.84 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-9.23M |
| Income | $-37.68M |
| Book/sh | $3.66 |
| Cash/sh | $10.39 |
| Employees | 24 |
Financial Ratios
| Quick Ratio | 1.66 |
| Current Ratio | 1.73 |
| Debt/Eq | 48.97 |
Returns & Margins
| ROA | -38.35% |
| ROE | -128.90% |
Ownership
| Insider Ownership | 0.41% |
| Institutional Ownership | 58.41% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.55 |
| P/B | 1.56 |
Analyst Data
| Recommendation | buy |
| Target Price | $12.67 |
Technical Indicators
| SMA20 | $5.62 |
| SMA50 | $6.07 |
| SMA200 | $8.40 |
| RSI | 47.65 |
| ATR | 0.4411 |
| Shares Float | 2.89M |
| Short Float | 4.74% |
| Short Ratio | 1.87 |
| Rel Volume | 0.96 |
Performance History
| Week | -1.55% |
| Month | +10.00% |
| Quarter | -23.01% |
| 6 Months | -36.51% |
| YTD | -51.07% |
| Year | -26.85% |
| 3 Years | -68.57% |
| 5 Years | -98.02% |
| 10 Years | -98.71% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-22 | $5.72 | 38,000 |
| 2026-06-18 | $5.59 | 73,100 |
| 2026-06-17 | $5.33 | 20,600 |
| 2026-06-16 | $5.50 | 55,600 |
| 2026-06-15 | $5.50 | 40,100 |
| 2026-06-12 | $5.81 | 30,400 |
| 2026-06-11 | $5.60 | 57,000 |
| 2026-06-10 | $5.13 | 72,000 |
| 2026-06-09 | $5.57 | 27,600 |
| 2026-06-08 | $5.47 | 28,900 |
| 2026-06-05 | $5.62 | 34,800 |
| 2026-06-04 | $6.00 | 49,400 |
| 2026-06-03 | $5.97 | 35,000 |
| 2026-06-02 | $5.89 | 25,200 |
| 2026-06-01 | $5.85 | 18,400 |
| 2026-05-29 | $5.77 | 29,700 |
| 2026-05-28 | $5.71 | 88,000 |
| 2026-05-27 | $5.52 | 39,300 |
| 2026-05-26 | $5.55 | 21,300 |
About Passage Bio, Inc.
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding Ã-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other programs for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is based in Philadelphia, Pennsylvania.
đ° Latest News
Passage Bio Inc (PASG) Stock: Should You Buy the Dip For 125% Upside?
Insider Monkey âĸ 2026-05-20T12:35:59Z
Sector Update: Health Care Stocks Softer Late Afternoon
MT Newswires âĸ 2026-04-21T19:57:47ZPassage Bio Faces Tougher FDA Road After Trial Shift, Wedbush Says
MT Newswires âĸ 2026-04-21T18:20:44ZPassage Bio Seen as Undervalued Despite FDA Setback, Oppenheimer Says
MT Newswires âĸ 2026-04-21T15:46:35ZWall Street Analysts Think Passage Bio (PASG) Could Surge 731%: Read This Before Placing a Bet
Zacks âĸ 2025-09-01T13:55:03Z
Wall Street Analysts Believe Passage Bio (PASG) Could Rally 1415.15%: Here's is How to Trade
Zacks âĸ 2025-08-15T13:55:02Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $43,151,000 | $65,167,000 | $102,999,000 | $135,394,000 |
| Other Income Expense | $-2,371,000 | $400,000 | $937,000 | $-731,000 |
| Other Non Operating Income Expenses | $3,774,000 | $5,633,000 | $6,327,000 | $2,269,000 |
| Operating Expense | $43,151,000 | $65,167,000 | $102,999,000 | $135,394,000 |
| General And Administrative Expense | $19,875,000 | $24,988,000 | $41,580,000 | $49,341,000 |
| Net Non Operating Interest Income Expense | - | - | - | $2,269,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-45,522,000 | $-64,767,000 | $-102,062,000 | $-136,125,000 |
| Normalized Income | $-39,377,000 | $-59,534,000 | $-96,672,000 | $-133,125,000 |
| Net Income From Continuing And Discontinued Operation | $-45,522,000 | $-64,767,000 | $-102,062,000 | $-136,125,000 |
| Total Operating Income As Reported | $-49,296,000 | $-70,400,000 | $-108,389,000 | $-138,394,000 |
| Net Income Common Stockholders | $-45,522,000 | $-64,767,000 | $-102,062,000 | $-136,125,000 |
| Net Income | $-45,522,000 | $-64,767,000 | $-102,062,000 | $-136,125,000 |
| Net Income Including Noncontrolling Interests | $-45,522,000 | $-64,767,000 | $-102,062,000 | $-136,125,000 |
| Net Income Continuous Operations | $-45,522,000 | $-64,767,000 | $-102,062,000 | $-136,125,000 |
| Pretax Income | $-45,522,000 | $-64,767,000 | $-102,062,000 | $-136,125,000 |
| Special Income Charges | $-6,145,000 | $-5,233,000 | $-5,390,000 | $-3,000,000 |
| Operating Income | $-43,151,000 | $-65,167,000 | $-102,999,000 | $-135,394,000 |
| Net Interest Income | - | - | - | $2,269,000 |
| Interest Income | - | - | - | $2,269,000 |
| Interest Income Non Operating | - | - | - | $2,269,000 |
| Per Share | ||||
| Diluted EPS | $-14.35 | $-21.40 | $-37.20 | $-50.00 |
| Basic EPS | $-14.35 | $-21.40 | $-37.20 | $-50.00 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-36,278,000 | $-56,853,000 | $-93,888,000 | $-128,715,000 |
| Total Unusual Items | $-6,145,000 | $-5,233,000 | $-5,390,000 | $-3,000,000 |
| Total Unusual Items Excluding Goodwill | $-6,145,000 | $-5,233,000 | $-5,390,000 | $-3,000,000 |
| Reconciled Depreciation | $728,000 | $3,081,000 | $3,721,000 | $3,679,000 |
| EBITDA (Bullshit earnings) | $-42,423,000 | $-62,086,000 | $-99,278,000 | $-131,715,000 |
| EBIT | $-43,151,000 | $-65,167,000 | $-102,999,000 | $-135,394,000 |
| Diluted Average Shares | $3,172,870 | $3,020,251 | $2,737,174 | $2,721,451 |
| Basic Average Shares | $3,172,870 | $3,020,251 | $2,737,174 | $2,721,451 |
| Diluted NI Availto Com Stockholders | $-45,522,000 | $-64,767,000 | $-102,062,000 | $-136,125,000 |
| Impairment Of Capital Assets | $6,145,000 | $5,233,000 | $5,390,000 | $0 |
| Research And Development | $23,276,000 | $40,179,000 | $61,419,000 | $86,053,000 |
| Selling General And Administration | $19,875,000 | $24,988,000 | $41,580,000 | $49,341,000 |
| Other Gand A | $19,875,000 | $24,988,000 | $41,580,000 | $49,341,000 |
| Write Off | - | $5,233,000 | $5,390,000 | $0 |
| Other Special Charges | - | - | - | $3,000,000 |
Fetched: 2026-06-18
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $18,755,000 | $61,261,000 | $111,283,000 | $201,366,000 |
| Total Assets | $62,281,000 | $102,412,000 | $150,545,000 | $243,549,000 |
| Total Non Current Assets | $14,519,000 | $23,597,000 | $32,586,000 | $46,505,000 |
| Other Non Current Assets | $244,000 | $463,000 | $433,000 | $4,267,000 |
| Current Assets | $47,762,000 | $78,815,000 | $117,959,000 | $197,044,000 |
| Other Current Assets | $629,000 | $838,000 | $923,000 | $926,000 |
| Prepaid Assets | $830,000 | $1,221,000 | $2,742,000 | $6,508,000 |
| Cash Cash Equivalents And Short Term Investments | $46,303,000 | $76,756,000 | $114,294,000 | $189,610,000 |
| Cash And Cash Equivalents | $46,303,000 | $37,573,000 | $21,709,000 | $34,601,000 |
| Cash Equivalents | $43,803,000 | $34,046,000 | $18,113,000 | $27,069,000 |
| Cash Financial | $2,500,000 | $3,527,000 | $3,596,000 | $7,532,000 |
| Debt | ||||
| Total Debt | $24,010,000 | $25,476,000 | $26,294,000 | $27,107,000 |
| Long Term Debt And Capital Lease Obligation | $20,443,000 | $21,788,000 | $22,921,000 | $23,832,000 |
| Current Debt And Capital Lease Obligation | $3,567,000 | $3,688,000 | $3,373,000 | $3,275,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $43,526,000 | $41,151,000 | $39,262,000 | $42,183,000 |
| Total Non Current Liabilities Net Minority Interest | $20,443,000 | $21,788,000 | $22,921,000 | $23,832,000 |
| Current Liabilities | $23,083,000 | $19,363,000 | $16,341,000 | $18,351,000 |
| Current Deferred Liabilities | $13,750,000 | $8,226,000 | $0 | - |
| Payables And Accrued Expenses | $3,026,000 | $3,044,000 | $6,332,000 | $6,630,000 |
| Payables | $2,037,000 | $742,000 | $3,298,000 | $4,065,000 |
| Accounts Payable | $1,113,000 | $742,000 | $1,298,000 | $4,065,000 |
| Non Current Deferred Liabilities | - | - | - | $0 |
| Equity | ||||
| Common Stock Equity | $18,755,000 | $61,261,000 | $111,283,000 | $201,366,000 |
| Total Equity Gross Minority Interest | $18,755,000 | $61,261,000 | $111,283,000 | $201,366,000 |
| Stockholders Equity | $18,755,000 | $61,261,000 | $111,283,000 | $201,366,000 |
| Gains Losses Not Affecting Retained Earnings | $0 | $8,000 | $-43,000 | $-966,000 |
| Retained Earnings | $-704,757,000 | $-659,235,000 | $-594,468,000 | $-492,406,000 |
| Other Equity Adjustments | - | $8,000 | $-43,000 | $-966,000 |
| Other | ||||
| Ordinary Shares Number | $3,182,810 | $3,103,088 | $2,747,206 | $2,730,734 |
| Share Issued | $3,182,810 | $3,103,088 | $2,747,206 | $2,730,734 |
| Tangible Book Value | $18,755,000 | $61,261,000 | $111,283,000 | $201,366,000 |
| Invested Capital | $18,755,000 | $61,261,000 | $111,283,000 | $201,366,000 |
| Working Capital | $24,679,000 | $59,452,000 | $101,618,000 | $178,693,000 |
| Capital Lease Obligations | $24,010,000 | $25,476,000 | $26,294,000 | $27,107,000 |
| Total Capitalization | $18,755,000 | $61,261,000 | $111,283,000 | $201,366,000 |
| Additional Paid In Capital | $723,512,000 | $720,488,000 | $705,789,000 | $694,733,000 |
| Capital Stock | $0 | $0 | $5,000 | $5,000 |
| Common Stock | $0 | $0 | $5,000 | $5,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $20,443,000 | $21,788,000 | $22,921,000 | $23,832,000 |
| Current Deferred Revenue | $13,750,000 | $8,226,000 | $0 | - |
| Current Capital Lease Obligation | $3,567,000 | $3,688,000 | $3,373,000 | $3,275,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $2,740,000 | $4,405,000 | $6,636,000 | $8,446,000 |
| Current Accrued Expenses | $989,000 | $2,302,000 | $3,034,000 | $2,565,000 |
| Dueto Related Parties Current | $924,000 | $0 | $2,000,000 | $0 |
| Net PPE | $14,275,000 | $23,134,000 | $32,153,000 | $42,238,000 |
| Accumulated Depreciation | $-3,917,000 | $-9,724,000 | $-7,236,000 | $-5,153,000 |
| Gross PPE | $18,192,000 | $32,858,000 | $39,389,000 | $47,391,000 |
| Leases | $6,510,000 | $7,386,000 | $10,213,000 | $13,506,000 |
| Other Properties | $10,168,000 | $23,823,000 | $26,923,000 | $29,695,000 |
| Machinery Furniture Equipment | $1,514,000 | $1,649,000 | $1,615,000 | $2,899,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $0 | $39,183,000 | $92,585,000 | $155,009,000 |
| Construction In Progress | - | $0 | $638,000 | $1,291,000 |
Fetched: 2026-06-18
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-31,509,000 | $-47,990,000 | $-78,410,000 | $-123,484,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-31,509,000 | $-47,956,000 | $-78,264,000 | $-118,210,000 |
| Cash Flow From Continuing Operating Activities | $-31,509,000 | $-47,956,000 | $-78,264,000 | $-118,210,000 |
| Operating Gains Losses | - | - | $463,000 | - |
| Investing Activities | ||||
| Investing Cash Flow | $40,216,000 | $54,946,000 | $65,237,000 | $25,199,000 |
| Cash Flow From Continuing Investing Activities | $40,216,000 | $54,946,000 | $65,237,000 | $25,199,000 |
| Capital Expenditure | - | $-34,000 | $-146,000 | $-5,274,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $8,742,000 | $0 | $0 |
| Financing Cash Flow | $23,000 | $8,874,000 | $135,000 | $-1,353,000 |
| Cash Flow From Continuing Financing Activities | $23,000 | $8,874,000 | $135,000 | $-1,353,000 |
| Net Common Stock Issuance | $0 | $8,742,000 | $0 | $0 |
| Common Stock Issuance | $0 | $8,742,000 | $0 | $0 |
| Net Other Financing Charges | - | - | - | $-1,786,000 |
| Other | ||||
| End Cash Position | $46,303,000 | $37,573,000 | $21,709,000 | $34,601,000 |
| Beginning Cash Position | $37,573,000 | $21,709,000 | $34,601,000 | $128,965,000 |
| Changes In Cash | $8,730,000 | $15,864,000 | $-12,892,000 | $-94,364,000 |
| Proceeds From Stock Option Exercised | $23,000 | $132,000 | $135,000 | $433,000 |
| Net Investment Purchase And Sale | $39,046,000 | $54,980,000 | $65,383,000 | $30,473,000 |
| Sale Of Investment | $39,046,000 | $143,150,000 | $194,815,000 | $188,308,000 |
| Purchase Of Investment | $0 | $-88,170,000 | $-129,432,000 | $-157,835,000 |
| Net PPE Purchase And Sale | $1,170,000 | $-34,000 | $-146,000 | $-2,274,000 |
| Sale Of PPE | $1,170,000 | $0 | - | - |
| Purchase Of PPE | $0 | $-34,000 | $-146,000 | $-2,274,000 |
| Change In Working Capital | $3,996,000 | $4,204,000 | $5,339,000 | $-8,491,000 |
| Change In Other Working Capital | $3,551,000 | $7,947,000 | $-133,000 | $463,000 |
| Change In Payables And Accrued Expense | $-174,000 | $-5,519,000 | $-2,131,000 | $-12,750,000 |
| Change In Accrued Expense | $-2,054,000 | $-4,963,000 | $659,000 | $-7,338,000 |
| Change In Payable | $1,880,000 | $-556,000 | $-2,790,000 | $-5,412,000 |
| Change In Account Payable | $1,880,000 | $-556,000 | $-2,790,000 | $-5,412,000 |
| Change In Prepaid Assets | $619,000 | $1,776,000 | $7,603,000 | $3,796,000 |
| Other Non Cash Items | $14,000 | - | - | $3,000,000 |
| Stock Based Compensation | $3,001,000 | $5,820,000 | $10,921,000 | $18,954,000 |
| Asset Impairment Charge | $6,145,000 | $5,233,000 | $5,390,000 | $0 |
| Amortization Of Securities | $129,000 | $-1,527,000 | $-2,036,000 | $773,000 |
| Depreciation Amortization Depletion | $728,000 | $3,081,000 | $3,721,000 | $3,679,000 |
| Depreciation And Amortization | $728,000 | $3,081,000 | $3,721,000 | $3,679,000 |
| Net Income From Continuing Operations | $-45,522,000 | $-64,767,000 | $-102,062,000 | $-136,125,000 |
| Gain Loss On Sale Of PPE | - | $0 | $463,000 | $0 |
| Net Intangibles Purchase And Sale | - | - | $0 | $-3,000,000 |
| Purchase Of Intangibles | - | - | $0 | $-3,000,000 |
Fetched: 2026-06-18